NCT06567119View on ClinicalTrials.gov

Preliminary Evaluation of the Safety and Tolerability of SPOT-mRNA01 Subcutaneously Administered in Healthy Subjects

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 12, 2025

Primary Completion Date

November 12, 2027

Study Completion Date

December 15, 2027

Conditions
Skin Aging
Interventions
BIOLOGICAL

SPOT-mRNA01

SPOT-mRNA01 (COL1A1 mRNA-loaded by EVs) ,single-dose subcutaneous injection

OTHER

Placebo

Sterile isotonic solution, subcutaneous injection

All Listed Sponsors
collaborator

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

OTHER

lead

SIPO Biotechnology Co. Ltd.

INDUSTRY